NOTE 9 – STOCKHOLDERS’ EQUITY
As of September 30, 2017, the Company had 400,000,000 shares of common stock authorized,
$0.0001 par value, of which 421,214,603 shares issued and outstanding
from the 11/30 statements. I was a touch off. but closer than you, and my main point still stands. they have barely diluted at all considering what they have achieved and relative to other pharm start ups.